RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
about
Is it time to abandon RHAMM/HMMR as a candidate antigen for immunotherapy of acute myeloid leukemia?Can immunotherapy specifically target acute myeloid leukemic stem cells?Dendritic cell-based immunotherapy for myeloid leukemias.Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers.Dendritic cell vaccine against leukemia: advances and perspectives.Targeting hyaluronic acid family for cancer chemoprevention and therapy.Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cellsRedox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors.Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells.
P2860
Q36366928-BC450B44-1ED8-43D4-8C78-3BAB6CF1552BQ36694901-C8E05055-7256-48E5-AF13-D76B949D00A9Q37420778-60E08D34-42A1-49E0-B27C-2B0DB5E0B923Q38199975-72B47777-19D7-4899-A4EA-F00D5C851B0BQ38210813-12C20108-DBDB-48F1-B53F-9E39CFF8BFE9Q38235792-DCC83351-A614-45CB-97A3-0F6A3D400041Q39067315-1E18674A-E43E-4FC2-A764-954EEBC24311Q39360428-DE644BE2-AAA2-4EE8-BD84-89F619A41FBCQ42113489-ABCD536C-1B33-4959-B2B2-0F9CC56ADAD5Q48375750-1FAE7B20-A4A7-42F9-BAAA-FE2B4ACD8B4AQ50447093-3EE6613E-0D7D-4E1B-970B-F32BD53AA6FBQ54324221-A0AD1A34-1B29-4890-9E2E-E2B02CC91629
P2860
RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
RHAMM/HMMR (CD168) is not an i ...... apy of acute myeloid leukemia.
@ast
RHAMM/HMMR (CD168) is not an i ...... apy of acute myeloid leukemia.
@en
type
label
RHAMM/HMMR (CD168) is not an i ...... apy of acute myeloid leukemia.
@ast
RHAMM/HMMR (CD168) is not an i ...... apy of acute myeloid leukemia.
@en
prefLabel
RHAMM/HMMR (CD168) is not an i ...... apy of acute myeloid leukemia.
@ast
RHAMM/HMMR (CD168) is not an i ...... apy of acute myeloid leukemia.
@en
P2093
P2860
P1433
P1476
RHAMM/HMMR (CD168) is not an i ...... apy of acute myeloid leukemia.
@en
P2093
Bart Vandekerckhove
Georges Leclercq
Glenn Goetgeluk
Greet Verstichel
Imke Velghe
Jan Philippé
Kris Thielemans
Stijn Vanhee
Sylvia Snauwaert
P2860
P304
P356
10.3324/HAEMATOL.2012.065581
P50
P577
2012-04-24T00:00:00Z